Long Term Safety Data Published on Cytori Technology for Breast Reconstruction After Oncologic Surgery & Radiation Therapy

SAN DIEGO, June 08, 2017 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (NASDAQ:CYTX) (“Cytori” or the “Company”) today announced the publication of long-term follow-up data reporting patient satisfaction and surveillance for cancer recurrences following use of Cytori Cell Therapy™ for breast reconstruction following partial mastectomy and radiation for breast cancer treatment.

This Cytori-supported, investigator-initiated study, which was peer-reviewed and published in June 2017 edition of Surgery Today, followed ten patients treated with a single therapeutic administration of Cytori Cell Therapy at Kyushu University. None of the ten patients experienced cancer recurrence or new cancer formation through a median of 8.5 years of follow up (range 5.1-8.9 years; mean 7.8±1.5 years).
Scarring and tissue volume loss, particularly following extirpative surgery and adjuvant radiation therapy remains a significant reconstructive problem for survivors of breast cancer. Cytori’s technology is available to doctors in Japan under the new regenerative medicine regulations for reconstructive purposes. Several pre-clinical and clinical studies suggest that Cytori Cell Therapy has potential to help alter markers and outcomes related to fibrosis characterized by tissue fibrosis (scar), irrespective of the etiology of the fibrosis.

Currently, there are three ongoing clinical trials involving Cytori Cell Therapy in which fibrosis is an important pathophysiologic feature of the primary disease: (1) Cytori’s Phase III STAR trial for hand manifestations of systemic scleroderma, (2) the investigator-initiated ADRESU trial in Japan for post-prostatectomy urinary incontinence and (3) Cytori’s RELIEF trial for thermal burns. The published report can be found at the following link: Ito et al, Surg Today (2017) DOI 10.1007/s00595-017-1544-4.

About Cytori Therapeutics, Inc.

Cytori is a therapeutics company developing regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for a variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy™ may provide benefits across multiple disease states and can be made available to the physician and patient at the point-of-care through Cytori’s proprietary technologies and products. Cytori Nanomedicine™ is developing encapsulated therapies for regenerative medicine and oncologic indications. For more information, visit www.cytori.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements, including, but not limited to, statements regarding potential benefits of Cytori Cell Therapy™ are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include: risks in the conduct of Cytori-conducted and investigator-conducted clinical trials; risks in the collection and results of clinical data; risks associated with final clinical outcomes; regulatory risks and uncertainties; risks related to dependence on third party performance; and other risks and uncertainties described under the "Risk Factors" section in Cytori's Securities and Exchange Commission Filings on Form 10-K and Form 10-Q. Cytori assumes no responsibility to update or revise any forward-looking statements contained in this press release to reflect events, trends or circumstances after the date of this communication.

CONTACT: Cytori Therapeutics, Inc.

Tiago Girao, 1.858.458.0900